Mast Therapeutics, Inc. (MSTX)


Mast Therapeutics is a development stage biopharmaceutical company focused on developing proprietary product candidates. Co.'s lead product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that is designed to improve microvascular blood flow with potential applications in treating a range of diseases and conditions, such as complications arising from sickle cell disease. In addition, Co. is developing ANX-514, a detergent-free formulation of the chemotherapy drug docetaxel, an intravenously-injected chemotherapy drug used to treat solid tumors.

View SEC Filings from MSTX instead.
Filers who had this stock in their top 10: 1
13F Filers holding this stock: 38
Aggregate shares on 06/30/2016: 23,798,374
Aggregate shares on 03/31/2016: 26,726,381
Percent change: -10.96%
Funds creating new positions: 8
Funds Adding to an existing position: 10
Funds closing out their position: 4
Funds reducing their position: 6
View recent insider trading info

13F Filers holding this stock

Quarter 1: Refresh

Changes in Holdings:

*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Schedule 13D and 13G filings submitted since 06/30/2016

Subscription required

Click here to report any possible errors with this stock listing.

Elevate your investments

or Learn more